MAPT and Alzheimer disease: Meanwhile, our data also indicate that metabolic clinical markers, including BMI, waist circumference, and serum insulin and glucose levels, are implicated in the prediction of p-tau protein levels in the CSF in AD, as explored in previous studies (Gonçalves et al., 2019; Lee et al., 2023).